Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialAchim Rittmeyer, David R. Gandara, Fabrice Barlési et al.|The Lancet|2016Cited by 4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerGiorgio V. Scagliotti, David R. Gandara, Purvish Parikh et al.|Journal of Clinical Oncology|2008Cited by 3.2k
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabDavid R. Gandara, David S. Shames, Jacob Silterra et al.|Nature Medicine|2018Cited by 1.2k
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLCChristian Rolfo, David R. Gandara, Philip C. Mack et al.|Journal of Thoracic Oncology|2018Cited by 661
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung CancerChristian Rolfo, David R. Gandara, Philip C. Mack et al.|Journal of Thoracic Oncology|2021Cited by 642